|View printer-friendly version|
|Blueprint Medicines to Present at 2017 RBC Capital Markets Global Healthcare Conference|
A live webcast of the presentation will be available by visiting the Investors section of Blueprint Medicines' website at http://ir.blueprintmedicines.com. A replay of the webcast will be archived on Blueprint Medicines' website for 30 days following the presentation.
Blueprint Medicines is developing a new generation of targeted and potent kinase medicines to improve the lives of patients with genomically defined diseases. Its approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Blueprint Medicines is advancing three programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma and systemic mastocytosis, as well as multiple programs in research and preclinical development. For more information, please visit www.blueprintmedicines.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/blueprint-medicines-to-present-at-2017-rbc-capital-markets-global-healthcare-conference-300405052.html
Investor Relations - Kristin Williams, Blueprint Medicines Corporation, 617-714-6674, email@example.com; Media Relations - Rachel Hutman, W20 Group, 301-801-5540, firstname.lastname@example.org